President Trump Signs Executive Order Imposing 100% Tariff on Overseas Drug Manufacturers

20 hours ago
3 min read

WASHINGTON — In a major move aimed at reshaping global pharmaceutical trade and lowering domestic prescription costs, President Donald Trump signed an executive order Thursday implementing a 100% tariff on imported patented pharmaceuticals and their active ingredients.

The policy targets high-cost, branded drugs produced overseas, using the threat of steep import taxes to incentivize pharmaceutical companies to align their pricing with other developed nations and to relocate their manufacturing facilities to the United States.

Here is a breakdown of the new policy, how it works, and its expected impact on the pharmaceutical industry.

The executive order outlines strict timelines and potential off-ramps for pharmaceutical manufacturers facing the new tax:

The tariff applies exclusively to imported patented and branded pharmaceutical products, as well as their active pharmaceutical ingredients (APIs).

Large pharmaceutical companies have a 120-day grace period to comply or negotiate with the administration before the steep duties take effect. Smaller manufacturers are granted a 180-day buffer.

Generic pharmaceuticals, which account for roughly 90% of the medicines dispensed in the United States, are currently exempt from the tariffs. The administration noted this exemption will be reassessed in one year.

Imports from five specific countries that have reached separate trade agreements with the United States are largely exempt from the new levies. Specialty, orphan, and veterinary drugs from these nations may also be spared.

The Trump administration has structured the tariff to force concessions from drugmakers, offering specific exemptions for companies willing to meet the White House's criteria:

"Most Favored Nation" Pricing Agreements: Companies that agree to lower their U.S. retail prices to match the lower costs charged in other high-income nations can secure multi-year tariff exemptions. According to reports, the government has already reached pricing agreements with 17 major pharmaceutical companies, including industry giants like Pfizer and AstraZeneca.

Manufacturers that commit to building new pharmaceutical plants in the U.S. can largely avoid the 100% tax. Companies actively constructing domestic facilities will face a reduced 20% tariff during the building phase. However, if the construction is not completed within four years, the tariff will revert to 100%.

The tariffs were enacted under Section 232 of the Trade Expansion Act of 1962, a provision that allows the president to adjust imports if they are deemed a threat to national security. The administration argues that heavy reliance on foreign manufacturing for critical medications and APIs poses a severe public health and security risk.

By leveraging Section 232, the administration bypassed the legal challenges that recently struck down other emergency tariffs at the Supreme Court, as the Section 232 process requires an extensive investigation by the Commerce Department. The White House reported that the impending tariffs have already spurred approximately $400 billion in new investment commitments from pharmaceutical companies seeking to expand their U.S. operations, with companies like Eli Lilly and Johnson & Johnson pledging billions to domestic facilities.

While the administration champions the move as a victory for American patients and workers, the industry's response has been mixed. Major pharmaceutical players with diverse portfolios and heavy capital have successfully navigated the new rules by striking early pricing deals and announcing U.S. plant expansions.

However, mid-sized and smaller biotech firms warn of potential disruptions. Industry groups representing these smaller companies argue they lack the diversified portfolios necessary to easily absorb the sudden cost increases or instantly pivot their manufacturing pipelines. Over the next 120 to 180 days, these firms will be rushing to finalize individual arrangements with the Department of Health and Human Services to avoid the looming 100% penalty.

-Johnnica Myrick